Clinical recommendations for antibacterial therapy of community-acquired infections: what should a practitioner pay attention to?

Results. The seminar featured presentations by Corresponding Member of the Russian Academy of Sciences, Rector of the Smolensk State Medical University, Chief freelance Specialist of the Ministry of Health of Russia on Clinical Microbiology and antimicrobial Resistance

S. Kozlov; Vice Director for Scientific Work of the Scientific Research Institute of Antimicrobial Therapy of Smolensk University, Candidate of Medical Sciences A. V. Dehnich; Associate Professor of the Department Phthisiopulmonology of Kazan State Medical University, Doctor of Medical Sciences I. Yu. Wiesel. Antibiotic resistance is one of the most serious global threats to human health, making it difficult to treat life-threatening infections. According to the forecast of the World Health Organization, the level of antibiotic resistance in the world may increase by 17% by 2050. This problem is extremely acute in cities with millions of inhabitants, which is associated with high population density, active migration processes, the growth of a stratum of unvaccinated people, outbreaks of ornithosis spread by pigeons, whose population is growing uncontrollably in megacities. The global situation of antibiotic resistance has only worsened since the COVID-19 pandemic. Conclusion. The increasing antibiotic resistance inside the population of cities with millions of inhabitants, especially after the COVID-19 pandemic, and the high risk of atypical (intracellular) infections characterized by bilateral damage of the nasopharynx in combination with damage of the lower respiratory tract, therapists should be informed about a rational choice of an effective antibacterial drug from the macrolide group that blocks not one or two, but three domains on the ribosome of the pathogen at once, exerting a triple bactericidal effect (spiramycin). Since this macrolide has avoided widespread use during the COVID-19 pandemic, infectious agents have not yet developed widespread resistance to it. 

1. Antibiotic resistance. https://www.who.int/ru/news-room/fact-sheets/detail/antibiotic-resistance. (In Russ.)

2. Van Bavel B., Berrang-Ford L., Moon K., Gudda Alexander F., Thornton J., Robinson R. F. S. and others. Intersections between climate change and antimicrobial resistance: a systematic scoping review. The Lancet Planetary Health. 2024; 12 (8): 1118-1128. Published: December 2024. Available from: https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(24)00273-0/fulltext.

3. Sommer M. O. A., Dantas G., Church G. M. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science. 2009; 325 (5944): 1128-1131.

4. Baturin V. A., Muravyeva A. A., Tkachev A. V., Afanasyev N. E., Kunitsina E. A. Accumulation of resistance to antibacterial agents in the post-cohort period in a polyclinic and a multidisciplinary hospital. Problemy standartizatsii v zdravookhranenii. 2021; 5-6: 50-54. DOI: 10.26347/1607-2502202105-06050-054. (In Russ.)

5. Jian-Qiang Su, Xin-Li An, Bing Li, Qing-Lin Chen, et al. Metagenomics of urban sewage identifies an extensively shared antibiotic resistome in China. Microbiome. 2017; 5: 8. DOI: 10.1186/s40168-017-0298-y. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-017-0298-y#citeas.

6. Stetsyuk O. U., Andreeva I. V., Kozlov R. С. Potential of spiramycin application in clinical practice. Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2009; 3 (11).https://cmac-journal.ru/publication/2009/3/cmac-2009-t11-n3-p218/cmac2009-t11-n3-p218.pdf. (In Russ.)

7. Strachunsky L. S., Kozlov S. N. Macrolides in modern clinical practice. N. Macrolides in modern clinical practice. http://old.antibiotic.ru/books/macrolid/mcld11.shtml. (In Russ.)

8. Appendix to the letter of FSBI ‘SCEEMP’ of the Ministry of Health of Russia from 04.03.2025 № 5792. https://grls.rosminzdrav.ru/Forum/Files/245379/Инф_письмо_цефподоксим_170325. (In Russ.)

9. The list of side effects of cefpodoxime drugs has been expanded. https://vademec.ru/news/2025/03/21/rasshiren-perechen-pobochnykheffektov-preparatov-s-tsefpodoksimom/. (In Russ.)

10. Butranova O. I., Zyryanov S. K., Abramova A. A. Spiramycin: past and future of an antibiotic with pleiotropic effects in the therapy of out-of-hospital infections. Farmatsiia i farmakologiia. 2024; 12 (2): 150-171. DOI: 10.19163/2307-9266-2024-12-2-150-171. (In Russ.)

11. Shishkina M. S., Lobova T. P., Mikhaylova V. V., Skvortsova A. N., Zuzgina S. V., Zinovieva O. Е. Review of the epizootic situation on chlamydia of animals and birds on the territory of the Russian Federation for the period from 2019 to 2021. Agrarnaya nauka. 2024; 380 (3): 57-61. https://doi.org/10.32634/08698155-2024-380-3-57-61. (In Russ.)

12. Pneumonia outbreak in Russia: which regions already have the infection, schools are closed for quarantine, symptoms and treatment of Mycoplasma pneumoniae: October 27, 2024. NGS.ru. https://ngs.ru/text/health/2024/10/27/74255792/. (In Russ.)

13. Global shortage of innovative antibiotics contributes to the emergence and spread of drug resistance. April 15, 2021 Departmental News Release: https://www.who.int/ru/news/item/15-04-2021-global-shortageof-innovative-antibiotics-fuels-emergence-andspread-of-drug-resistance. (In Russ.)

14. Khashukoeva A. Z., Agaeva M. I., Savchenko T. N., et al. Rational use of antimicrobials in obstetric practice taking into account growing antibiotic resistance. Lechaschi Vrach. 2024; (6). https://www.lvrach.ru/2024/06/15439114?ysclid=m7lnc4b6zn673945954. (In Russ.)

15. List of effective antibiotics is rapidly decreasing. Izvestiya. https://iz.ru/1396034/valeriia-nodelman/perechen-effektivnykh-antibiotikov-stremitelno-sokrashchaetsia (In Russ.).